Articles related to Hematology

“The enrichment of diverse immune‐related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies.”

“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy. This reprogramming made them significantly better at recognizing and killing cancer cells.”

“The damage to DNA lasts a lifetime. Probably the biggest concern is the increased risk of other cancers developing as a result of exposure to prior chemotherapy.”

Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.

The analysis demonstrates that periprocedural bleeding rates with factor XI inhibition were comparable to or lower than traditional anticoagulation, with only 0.9% of procedures within 30 days of abelacimab dosing experiencing major bleeding complications.

Cancer research infrastructure faces its most severe funding crisis in over two decades, with institutions forced to choose between maintaining current studies and preserving workforce capacity for future breakthroughs.